Cagrilintide Research Guide
Research Overview
Cagrilintide (AM833) is an investigational long-acting analogue of the peptide hormone amylin, studied in preclinical and clinical metabolic research. Amylin signals through a receptor complex formed by the calcitonin receptor paired with receptor-activity-modifying proteins (RAMP1-3). This is a research compound and is not intended for human consumption.
Structural & Class Overview
Long-acting synthetic amylin analogue in the amylin/calcitonin peptide family. Acts at amylin receptors (AMY1R and AMY3R), heterodimeric complexes of the calcitonin receptor with RAMP1 or RAMP3. Distinct in mechanism from the incretin (GLP-1/GIP) peptide class.
General Research Interest
Research interest includes amylin-receptor subtype signaling (AMY1R/AMY3R), central nervous system pathways for amylin action in preclinical models, long-acting analogue chemistry and stability, and combination pharmacology with incretin-class peptides in laboratory research.
Storage Considerations
Typically supplied as a lyophilized powder. Standard research handling keeps lyophilized material cold and protected from light and humidity; reconstituted solutions are generally refrigerated and used within a limited period. For laboratory research handling only.
Testing & Quality Considerations
Quality considerations include HPLC purity assessment, mass-spectrometry identity confirmation, and verification of each lot against its Certificate of Analysis (COA). Public research information on this investigational compound is limited and evolving; this page will be expanded as additional documentation is reviewed.
References
- Development of Cagrilintide, a Long-Acting Amylin Analogue (J. Med. Chem.)
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 (PMC)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
